Parameter | Statistic | PBO lactose
(n = 32) | PBO ELX
(n = 34) | OXY IR 15 mg (n = 32) | OXY IR 30 mg (n = 32) | ELX 100 mg (n = 32) | ELX 200 mg (n = 32) |
---|---|---|---|---|---|---|---|

Overall Drug Liking VAS | |||||||

At 12 h | Mean (S.D.) | 43.8 (16.8) | 37.6 (22.9) | 76.4 (25.3) | 80.9 (22.8) | 20.7 (26.9) | 17.0 (26.7) |

Median | 50.0 | 50.0 | 76.0 | 88.0 | 6.5 | 0.0 | |

P value^{a} | — | NS | *** | *** | *** ^{§§ ††† ‡‡‡} | *** ^{§§§ ††† ‡‡‡} | |

Take Drug Again VAS | |||||||

At 12 h | Mean (S.D.) | 6.6 (17.7) | 7.0 (19.0) | 78.4 (30.5) | 81.4 (22.5) | 15.3 (27.5) | 9.4 (22.5) |

Median | 0.0 | 0.0 | 94.0 | 94.0 | 0.0 | 0.0 | |

P value^{b} | — | NS | *** | *** | ^{††† ‡‡‡} | ^{††† ‡‡‡} | |

Bad Effects VAS | |||||||

E_{max} | Mean (S.D.) | 2.2 (8.8) | 17.4 (25.0) | 22.6 (28.2) | 35.2 (35.0) | 62.8 (38.7) | 74.2 (32.0) |

Median | 0.0 | 0.0 | 11.5 | 26.0 | 74.5 | 83.5 | |

P value^{b} | — | ^{*} | ^{*} | *** | *** ^{§§§ ††† ‡‡} | *** ^{§§§ ††† ‡‡‡} | |

Pupil diameter | |||||||

MPC | Mean (S.D.) | 0.6 (0.5) | 0.5 (0.5) | 2.2 (0.8) | 2.7 (0.8) | 1.1 (0.6) | 1.1 (0.6) |

Median | 0.6 | 0.5 | 2.2 | 2.7 | 1.0 | 1.1 | |

P value^{a} | — | — | *** | *** | *** ^{§§§ ††† ‡‡‡} | *** ^{§§§ ††† ‡‡‡} |

ELX, eluxadoline; LS, least squares; MPC, maximum pupil constriction; NS, not significant; OXY IR, oxycodone immediate release; PBO, placebo.

↵

^{a}*P*values are for pairwise comparisons of LS mean differences between treatments.↵

^{b}*P*values are for pairwise comparisons of median differences between treatments. Both assessed using the Wilcoxon signed-rank test.↵* Significant versus PBO lactose (

*P*< 0.05);***significant versus PBO lactose (*P*< 0.0001);^{§§}significant versus PBO ELX (*P*< 0.01);^{§§§}significant versus PBO ELX (*P*< 0.0001);^{†††}significant versus OXY IR 15 mg (*P*< 0.0001);^{‡‡}significant versus OXY IR 30 mg (*P*< 0.01);^{‡‡‡}significant versus OXY IR 30 mg (*P*< 0.0001).